Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-02T04:15:10.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-26T01:04:15.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, v2.16.6, and the previous version, v2.16.5, has been removed. Additionally, a date of July 17, 2025, has been added.
    Difference
    0.6%
    Check dated 2025-07-18T22:10:19.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-11T17:55:12.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page has removed specific information regarding the modernization of ClinicalTrials.gov data ingest expected in July 2025, along with the previous revision details.
    Difference
    5%
    Check dated 2025-07-04T13:17:27.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    4%
    Check dated 2025-06-20T06:42:18.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.